Novo Ventures, the ventures arm of Novo Holdings, today announced that it has co-led the oversubscribed $83 million Series C financing in LAVA Therapeutics, a Dutch and US biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies. 17 September 2020
Adding BB Pureos Bioventures to its list of investors, France’s ImCheck Therapeutics has boosted its series B financing to 54 million euros ($64 million). 16 September 2020
Gilead Sciences today announced that the US Food and Drug Administration has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly-diagnosed myelodysplastic syndrome (MDS). 15 September 2020
Dutch NK-cell specialist Kiadis Pharma has received $9.5 million in funding for K-NK-ID101, via the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program. 15 September 2020
Sweden’s Orexo has filed a patent infringement action in the US District Court for the District of New Jersey against India’s Sun Pharmaceutical Industries and certain of its subsidiaries. 14 September 2020
The US regulator has granted Breakthrough Therapy designation to Sanofi’s Dupixent (dupilumab) in eosinophilic esophagitis (EoE), based on positive results from Part A of a Phase III trial. 14 September 2020
Clinical trials for the AstraZeneca and Oxford University COVID-19 vaccine, AZD1222, have resumed in the UK, following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the UK drug major announced today. 12 September 2020
The UK’s reimbursement agency has provided a positive decision on AstraZeneca’s Tagrisso (osimertinib) for certain people with locally-advanced or metastatic non-small cell lung cancer (NSCLC). 11 September 2020
The European Commission today announced that it will support with 4 million euros ($4.7 million) a new research project, SUPPORT-E, that will coordinate efforts to determine if COVID-19 convalescent plasma transfusion – using plasma from patients who recovered from the disease - is an effective and safe treatment. 11 September 2020
Merck KGaA’s US biotech arm MilliporeSigma has announced a $65 million expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) manufacturing capabilities at its Wisconsin, USA-based facility. 11 September 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Landsteiner Scientific pharmaceutical company have announced an agreement for the supply of 32 million doses of the Russian Sputnik V COVID-19 vaccine to Mexico (25% of population). 9 September 2020
California’s Exelixis has partnered with Swiss firm NBE-Therapeutics to discover and develop multiple antibody-drug conjugates (ADCs) in oncology. 8 September 2020
Tokyo’s Eisai is to acquire the Japanese rights to Parkinson's disease treatment Equfina (safinamide mesilate) from Meiji Seika Pharma. 7 September 2020
Shares of China-based biotech BeiGene are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective today (September 7), and traded up 3% to HK$146.20 by late afternoon. 7 September 2020
Russia has highlighted the publication of a scientific article on the results of Phase I/II clinical trials on its coronavirus vaccine, Sputnik V. 4 September 2020
A number of leadership changes at Belgian biotech firm Promethera Biosciences are underway, after key members of the management team resigned from their positions. 2 September 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024